Roberto Cuca, Chief Operating Officer and Chief Financial Officer of TELA Bio Inc (TELA, Financial), purchased 64,444 shares of the company on October 24, 2024, as reported in a recent SEC Filing. Following this transaction, the insider now owns 155,388 shares of TELA Bio Inc.
TELA Bio Inc is a company that focuses on the development and marketing of a new category of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company offers a broad portfolio of products that are used in hernia repair, abdominal wall reconstruction, and plastic and reconstructive surgery.
Over the past year, Roberto Cuca has increased his holdings in TELA Bio Inc by purchasing a total of 74,444 shares. There have been no sales recorded by the insider during this period.
The insider transaction history for TELA Bio Inc shows a trend of more insider buying than selling over the past year, with 7 insider buys and only 1 insider sell.
On the date of the latest purchase by the insider, shares of TELA Bio Inc were trading at $2.25. This valuation gives the company a market cap of approximately $63.763 million.
According to the GF Value, the intrinsic value of TELA Bio Inc is estimated at $10.56 per share, suggesting that the stock might be undervalued. The price-to-GF-Value ratio stands at 0.21, indicating the stock is a Possible Value Trap, Think Twice.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted by a GuruFocus factor based on past returns and growth, and future business performance estimates from analysts.
This recent insider purchase could signal a positive outlook from the insider regarding the company's future performance, despite the current market valuation suggesting caution.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
